keyword
https://read.qxmd.com/read/38710241/targeting-lrp6-a-new-strategy-for-cancer-therapy
#1
REVIEW
Wei Xue, Bo Zhu, Kaili Zhao, Qiuju Huang, Hua Luo, Yiwen Shou, Zhaoquan Huang, Hongwei Guo
Targeting specific molecular drivers of tumor growth is a key approach in cancer therapy. Among these targets, the low-density lipoprotein receptor-related protein 6 (LRP6), a vital component of the Wnt signaling pathway, has emerged as an intriguing candidate. As a cell-surface receptor and vital co-receptor, LRP6 is frequently overexpressed in various cancer types, implicating its pivotal role in driving tumor progression. The pursuit of LRP6 as a target for cancer treatment has gained substantial traction, offering a promising avenue for therapeutic intervention...
May 6, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38679656/sulfonamide-bioisosteres-of-niclosamide-enhance-antibacterial-activity-of-colistin-and-bacitracin
#2
JOURNAL ARTICLE
Liam Berry, Danyel Ramirez, Ronald Domalaon, Frank Schweizer
Multicomponent therapy combining antibiotics with enhancer molecules known as adjuvants is an emerging strategy to combat antimicrobial resistance. Niclosamide is a clinically relevant anthelmintic drug with potential to be repurposed for its inherent antibacterial activity against Gram-positive bacteria and its ability to potentiate the antibacterial activity of colistin against susceptible and resistant Gram-negative bacteria. Herein, sulfonamide analogs of niclosamide were prepared and found to enhance colistin activity against Gram-negative bacteria...
April 28, 2024: ChemMedChem
https://read.qxmd.com/read/38677923/corrigendum-to%C3%A2-pharmacokinetic-considerations-for-enhancing-drug-repurposing-opportunities-of-anthelmintics-niclosamide-as-a-case-study-biomed-pharmacother-173-2024-116394
#3
Jeong In Seo, Geun-Woo Jin, Hye Hyun Yoo
No abstract text is available yet for this article.
April 26, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38666027/machine-learning-based-identification-of-a-consensus-immune-derived-gene-signature-to-improve-head-and-neck-squamous-cell-carcinoma-therapy-and-outcome
#4
JOURNAL ARTICLE
Xueying Hu, Haiqun Dong, Wen Qin, Ying Bin, Wenhua Huang, Min Kang, Rensheng Wang
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC), an extremely aggressive tumor, is often associated with poor outcomes. The standard anatomy-based tumor-node-metastasis staging system does not satisfy the requirements for screening treatment-sensitive patients. Thus, an ideal biomarker leading to precise screening and treatment of HNSCC is urgently needed. METHODS: Ten machine learning algorithms-Lasso, Ridge, stepwise Cox, CoxBoost, elastic network (Enet), partial least squares regression for Cox (plsRcox), random survival forest (RSF), generalized boosted regression modelling (GBM), supervised principal components (SuperPC), and survival support vector machine (survival-SVM)-as well as 85 algorithm combinations were applied to construct and identify a consensus immune-derived gene signature (CIDGS)...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38624214/molluscicide-screening-and-identification-of-novel-targets-against-pomacea-canaliculata
#5
JOURNAL ARTICLE
Guoli Qu, Jiakai Yao, Jie Wang, Xiaofei Zhang, Jianrong Dai, Haonan Yu, Yang Dai, Yuntian Xing
BACKGROUND: Due to the non-availability of any clear targets for molluscicides against Pomacea canaliculata (P. canaliculata), target-based screening strategy cannot be employed. In this study, the molluscicidal effects of typical pesticides on P. canaliculata were evaluated to obtain the molluscicide target. A series of arylpyrrole compounds were synthesized based on the discovered target, and the structure-activity relationship was explored. A preliminary strategy for screening molluscicides based on specific targets was also developed...
April 16, 2024: Pest Management Science
https://read.qxmd.com/read/38608448/stat3-promotes-cytoplasmic-nuclear-translocation-of-rna-binding-protein-hur-to-inhibit-il-1%C3%AE-induced-il-8-production
#6
JOURNAL ARTICLE
Jiangwen Long, Wang Zhao, Yangen Xiang, Yufei Wang, Wei Xiang, Xueting Liu, Manli Jiang, Yinghui Song, Jinyue Hu
Signal transducer and activator of transcription 3 (STAT3) functions to regulate inflammation and immune response, but its mechanism is not fully understood. We report here that STAT3 inhibitors Stattic and Niclosamide up-regulated IL-1β-induced IL-8 production in C33A, CaSki, and Siha cervical cancer cells. As expected, IL-1β-induced IL-8 production was also up-regulated through the molecular inhibition of STAT3 by use of CRISPR/Cas9 technology. Unexpectedly, IL-1β induced IL-8 production via activating ERK and P38 signal pathways, but neither STAT3 inhibitors nor STAT3 knockout affected IL-1β-induced signal transduction, suggesting that STAT3 decreases IL-8 production not via inhibition of signal transduction...
April 11, 2024: International Immunopharmacology
https://read.qxmd.com/read/38569269/a-randomized-trial-to-assess-the-acceleration-of-viral-clearance-by-the-combination-favipiravir-ivermectin-niclosamide-in-mild-to-moderate-covid-19-adult-patients-fincov
#7
JOURNAL ARTICLE
Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Panisadee Avirutnan, Kunlakanya Jitobaom, Prasert Auewarakul
BACKGROUND: The efficacy of the viral clearance and clinical outcomes of favipiravir (FPV) in outpatients being treated for coronavirus disease 2019 (COVID-19) is unclear. Ivermectin (IVM), niclosamide (NCL), and FPV demonstrated synergistic effects in vitro for exceed 78% inhibiting severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) replication. METHODS: A phase 2, open-label, 1:1, randomized, controlled trial was conducted on Thai patients with mild-to-moderate COVID-19 who received either combination FPV/IVM/NCL therapy or FPV alone to assess the rate of viral clearance among individuals with mild-to-moderate COVID-19...
March 29, 2024: Journal of Infection and Public Health
https://read.qxmd.com/read/38555408/design-and-fabrication-of-electrochemical-sensor-based-on-nio-ni-c-fe-3-o-4-ceo-2-for-the-determination-of-niclosamide
#8
JOURNAL ARTICLE
Setayesh Darvishi, Ali A Ensafi, Kimia Zarean Mousaabadi
In this study, we aimed to enhance and accelerate the electrochemical properties of a glassy carbon-based voltammetric sensor electrode. This was achieved through the modification of the electrode using a nanocomposite derived from a metal-organic framework, which was embedded onto a substrate consisting of metal oxide nanoparticles. The final product was an electrocatalyst denoted as NiO/Ni@C-Fe3 O4 /CeO2 , tailored for the detection of the drug niclosamide. Several techniques, including FT-IR, XRD, XPS, FE-SEM, TEM, and EDS, were employed to characterize the structure and morphology of this newly formed electroactive catalyst...
March 30, 2024: Scientific Reports
https://read.qxmd.com/read/38539825/induction-of-oxidative-stress-and-ferroptosis-in-triple-negative-breast-cancer-cells-by-niclosamide-via-blockade-of-the-function-and-expression-of-slc38a5-and-slc7a11
#9
JOURNAL ARTICLE
Marilyn Mathew, Sathish Sivaprakasam, Gunadharini Dharmalingam-Nandagopal, Souad R Sennoune, Nhi T Nguyen, Valeria Jaramillo-Martinez, Yangzom D Bhutia, Vadivel Ganapathy
The amino acid transporters SLC38A5 and SLC7A11 are upregulated in triple-negative breast cancer (TNBC). SLC38A5 transports glutamine, methionine, glycine and serine, and therefore activates mTOR signaling and induces epigenetic modifications. SLC7A11 transports cystine and increases the cellular levels of glutathione, which protects against oxidative stress and lipid peroxidation via glutathione peroxidase, a seleno (Se)-enzyme. The primary source of Se is dietary Se-methionine (Se-Met). Since SLC38A5 transports methionine, we examined its role in Se-Met uptake in TNBC cells...
February 27, 2024: Antioxidants (Basel, Switzerland)
https://read.qxmd.com/read/38516100/early-treatment-with-fluvoxamine-bromhexine-cyproheptadine-and-niclosamide-to-prevent-clinical-deterioration-in-patients-with-symptomatic-covid-19-a-randomized-clinical-trial
#10
JOURNAL ARTICLE
Dhammika Leshan Wannigama, Cameron Hurst, Phatthranit Phattharapornjaroen, Parichart Hongsing, Natchalaikorn Sirichumroonwit, Kanokpoj Chanpiwat, Ali Hosseini Rad S M, Robin James Storer, Puey Ounjai, Phitsanuruk Kanthawee, Natharin Ngamwongsatit, Rosalyn Kupwiwat, Chaisit Kupwiwat, James Michael Brimson, Naveen Kumar Devanga Ragupathi, Somrat Charuluxananan, Asada Leelahavanichkul, Talerngsak Kanjanabuch, Paul G Higgins, Vishnu Nayak Badavath, Mohan Amarasiri, Valerie Verhasselt, Anthony Kicic, Tanittha Chatsuwan, Kashif Pirzada, Farid Jalali, Angela M Reiersen, Shuichi Abe, Hitoshi Ishikawa
BACKGROUND: Repurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials have studied combinations of these agents. The aim of this trial was to assess the effectiveness of affordable, widely available, repurposed drugs used in combination for treatment of COVID-19, which may be particularly relevant to low-resource countries. METHODS: We conducted an open-label, randomized, outpatient, controlled trial in Thailand from October 1, 2021, to June 21, 2022, to assess whether early treatment within 48-h of symptoms onset with combinations of fluvoxamine, bromhexine, cyproheptadine, and niclosamide, given to adults with confirmed mild SARS-CoV-2 infection, can prevent 28-day clinical deterioration compared to standard care...
April 2024: EClinicalMedicine
https://read.qxmd.com/read/38510268/dehydration-of-niclosamide-monohydrate-polymorphs-different-mechanistic-pathways-to-the-same-product
#11
JOURNAL ARTICLE
Jen E Mann, Renee Gao, Jennifer A Swift
Many active pharmaceutical ingredients (APIs) can crystallize as hydrates or anhydrates, the relative stability of which depends on their internal structures as well as the external environment. Hydrates may dehydrate unexpectedly or intentionally, though the molecular-level mechanisms by which such transformations occur are difficult to predict a priori . Niclosamide is an anthelmintic drug on the World Health Organization's "List of Essential Medicines" that crystallizes in two monohydrate forms: HA and HB ...
July 5, 2023: Crystal Growth & Design
https://read.qxmd.com/read/38500681/lipid-based-self-microemulsion-of-niclosamide-achieved-enhanced-oral-delivery-and-anti-tumor-efficacy-in-orthotopic-patient-derived-xenograft-of-hepatocellular-carcinoma-in-mice
#12
JOURNAL ARTICLE
Yi Liu, David Quintanar Guerrero, David Lechuga-Ballesteros, Mingdian Tan, Faiz Ahmad, Bilal Aleiwi, Edmund Lee Ellsworth, Bin Chen, Mei-Sze Chua, Samuel So
INTRODUCTION: We previously identified niclosamide as a promising repurposed drug candidate for hepatocellular carcinoma (HCC) treatment. However, it is poorly water soluble, limiting its tissue bioavailability and clinical application. To overcome these challenges, we developed an orally bioavailable self-microemulsifying drug delivery system encapsulating niclosamide (Nic-SMEDDS). METHODS: Nic-SMEDDS was synthesized and characterized for its physicochemical properties, in vivo pharmacokinetics and absorption mechanisms, and in vivo therapeutic efficacy in an orthotopic patient-derived xenograft (PDX)-HCC mouse model...
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38493058/neuroprotective-effects-of-niclosamide-on-disease-progression-via-inflammatory-pathways-modulation-in-sod1-g93a-and-fus-associated-amyotrophic-lateral-sclerosis-models
#13
JOURNAL ARTICLE
Martina Milani, Ilaria Della Valle, Simona Rossi, Paola Fabbrizio, Cassandra Margotta, Giovanni Nardo, Mauro Cozzolino, Nadia D'Ambrosi, Savina Apolloni
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease influenced by genetic, epigenetic, and environmental factors, resulting in dysfunction in cellular and molecular pathways. The limited efficacy of current treatments highlights the need for combination therapies targeting multiple aspects of the disease. Niclosamide, an anthelminthic drug listed as an essential medicine, has been repurposed in clinical trials for different diseases due to its anti-inflammatory and anti-fibrotic properties...
March 15, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38466550/in-vitro-activity-of-the-anthelmintic-drug-niclosamide-against-sporothrix-spp-strains-with-distinct-genetic-and-antifungal-susceptibility-backgrounds
#14
JOURNAL ARTICLE
Mariana Lucy Mesquita Ramos, Fernando Almeida-Silva, Vanessa Brito de Souza Rabello, Juliana Nahal, Maria Helena Galdino Figueiredo-Carvalho, Andrea Reis Bernardes-Engemann, Vanice Rodrigues Poester, Melissa Orzechowski Xavier, Wieland Meyer, Rosely Maria Zancopé-Oliveira, Susana Frases, Rodrigo Almeida-Paes
The drugs available to treat sporotrichosis, an important yet neglected fungal infection, are limited. Some Sporothrix spp. strains present reduced susceptibility to these antifungals. Furthermore, some patients may not be indicated to use these drugs, while others may not respond to the therapy. The anthelmintic drug niclosamide is fungicidal against the Sporothrix brasiliensis type strain. This study aimed to evaluate whether niclosamide also has antifungal activity against Sporothrix globosa, Sporothrix schenckii and other S...
March 11, 2024: Brazilian Journal of Microbiology: [publication of the Brazilian Society for Microbiology]
https://read.qxmd.com/read/38461686/pharmacokinetic-considerations-for-enhancing-drug-repurposing-opportunities-of-anthelmintics-niclosamide-as-a-case-study
#15
JOURNAL ARTICLE
Jeong In Seo, Geun-Woo Jin, Hye Hyun Yoo
Recently, anthelmintics have showcased versatile therapeutic potential in addressing various diseases, positioning them as promising candidates for drug repurposing. However, challenges such as low bioavailability and a lack of a solid pharmacokinetic basis impede successful repurposing. To overcome these flaws, we aimed to investigate the key pharmacokinetic factors of anthelmintics mainly focusing on the absorption, distribution, and metabolism profiles by employing niclosamide (NIC) as a model drug. The intestinal permeability of NIC is significantly influenced by solubility and doesn't function as a substrate for efflux transporters...
March 9, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38459564/cd146-cafs-promote-progression-of-endometrial-cancer-by-inducing-angiogenesis-and-vasculogenic-mimicry-via-il-10-jak1-stat3-pathway
#16
JOURNAL ARTICLE
Zhicheng Yu, Qian Zhang, Sitian Wei, Yang Zhang, Ting Zhou, Qi Zhang, Rui Shi, Dmitry Zinovkin, Zahidul Islam Pranjol, Jun Zhang, Hongbo Wang
Heterogeneous cancer-associated fibroblasts (CAFs) play important roles in cancer progression. However, the specific biological functions and regulatory mechanisms involved in endometrial cancer have yet to be elucidated. We aimed to explore the potential mechanisms of heterogeneous CAFs in promoting endometrial cancer progression. The presence of melanoma cell adhesion molecule (MCAM; CD146) positive CAFs was confirmed by tissue multi-immunofluorescence (mIF), and fluorescence activated cell sorting (FACS)...
March 8, 2024: Cell Communication and Signaling: CCS
https://read.qxmd.com/read/38455402/regulating-tkt-activity-inhibits-proliferation-of-human-acute-lymphoblastic-leukemia-cells
#17
JOURNAL ARTICLE
Fang-Liang Huang, Yao-Ming Chang, Cheng-Yung Lin, Sheng-Jie Yu, Jing-Tong Fu, Ting-Yu Chou, Sih-Wen Yeh, En-Chih Liao, Chia-Ling Li
Among pediatric blood cancers, acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy. Within ALL, T-cell acute lymphoblastic leukemia (T-ALL) accounts for 10 to 15% of all pediatric cases, and ~25% of adult cases. For T-ALL, its recurrence and relapse after treatment remain problematic. Therefore, it is necessary to develop new therapies for T-ALL. Recent studies suggested regulating energy metabolism is a novel approach to inhibit tumor growth, likely a promising treatment. Transketolase (TKT) is an important enzyme for modulating glucose metabolize in the pentose phosphate pathway (PPP)...
2024: American Journal of Cancer Research
https://read.qxmd.com/read/38434573/niclosamide-encapsulated-lipid-nanoparticles-for-the-reversal-of-pulmonary-fibrosis
#18
JOURNAL ARTICLE
Yan Yu, Hongyao Liu, Liping Yuan, Meng Pan, Zhongwu Bei, Tinghong Ye, Zhiyong Qian
Pulmonary fibrosis (PF) is a serious and progressive fibrotic interstitial lung disease that is possibly life-threatening and that is characterized by fibroblast accumulation and collagen deposition. Nintedanib and pirfenidone are currently the only two FDA-approved oral medicines for PF. Some drugs such as antihelminthic drug niclosamide (Ncl) have shown promising therapeutic potentials for PF treatment. Unfortunately, poor aqueous solubility problems obstruct clinical application of these drugs. Herein, we prepared Ncl-encapsulated lipid nanoparticles (Ncl-Lips) for pulmonary fibrosis therapy...
April 2024: Materials today. Bio
https://read.qxmd.com/read/38432118/computational-drug-repositioning-identifies-niclosamide-and-tribromsalan-as-inhibitors-of-mycobacterium-tuberculosis-and-mycobacterium-abscessus
#19
JOURNAL ARTICLE
Jeremy J Yang, Aaron Goff, David J Wild, Ying Ding, Ayano Annis, Randy Kerber, Brian Foote, Anurag Passi, Joel L Duerksen, Shelley London, Ana C Puhl, Thomas R Lane, Miriam Braunstein, Simon J Waddell, Sean Ekins
Tuberculosis (TB) is still a major global health challenge, killing over 1.5 million people each year, and hence, there is a need to identify and develop novel treatments for Mycobacterium tuberculosis (M. tuberculosis). The prevalence of infections caused by nontuberculous mycobacteria (NTM) is also increasing and has overtaken TB cases in the United States and much of the developed world. Mycobacterium abscessus (M. abscessus) is one of the most frequently encountered NTM and is difficult to treat. We describe the use of drug-disease association using a semantic knowledge graph approach combined with machine learning models that has enabled the identification of several molecules for testing anti-mycobacterial activity...
February 27, 2024: Tuberculosis
https://read.qxmd.com/read/38399310/repurposed-drugs-that-activate-autophagy-in-filarial-worms-act-as-effective-macrofilaricides
#20
JOURNAL ARTICLE
Denis Voronin, Nancy Tricoche, Ricardo Peguero, Anna Maria Kaminska, Elodie Ghedin, Judy A Sakanari, Sara Lustigman
Onchocerciasis and lymphatic filariasis are two neglected tropical diseases caused by filarial nematodes that utilize insect vectors for transmission to their human hosts. Current control strategies are based on annual or biannual mass drug administration (MDA) of the drugs Ivermectin or Ivermectin plus Albendazole, respectively. These drug regimens kill the first-stage larvae of filarial worms (i.e., microfilariae) and interrupt the transmission of infections. MDA programs for these microfilaricidal drugs must be given over the lifetime of the filarial adult worms, which can reach 15 years in the case of Onchocerca volvulus ...
February 9, 2024: Pharmaceutics
keyword
keyword
111778
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.